Latest Advances in Lung Cancer Research

Research study shows pacritinib has the ability to selectively target in squamous cell but does not impact normal glucose metabolism.

Removing only a portion of lobes is as effective as the traditional surgery for some patients with early-stage lung cancer.

The ASCO Living Guideline for advanced non-small cell lung cancer (NSCLC) with driver alterations has gotten its first update, with data from recent studies.

Amgen’s Lumakras cut the risk of disease progression or death by 34% compared with the chemotherapy docetaxel in previously treated KRAS G12C-mutated non-small cell lung cancer.

Fox Chase Cancer Center highlights advances in NSCLC treatment with immunotherapy and the promise of amivantamab for specific genetic mutations, alongside ongoing SCLC research.

Research shows combining KRAS inhibitors and immunotherapy could improve treatment for certain lung cancers, based on promising mouse studies.

Opdivo plus chemo reduces death risk by 43% pre-surgery in NSCLC patients, leading to FDA approval, with broad patient eligibility regardless of PD-L1 levels.

FDA skepticism challenges sintilimab’s approval for NSCLC, citing concerns over trial data exclusivity from China and its less favored endpoint of PFS.

FDA grants breakthrough designation to FoundationOne Tracker, an assay for detecting MRD in cancer, aiding treatment decisions and relapse monitoring.

FDA grants breakthrough designation to CLN-081, a targeted therapy for NSCLC with EGFR exon 20 mutations, showing promise in ongoing clinical trials.

[NEED EXTERNAL LINK TO ARTICLE]

Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial for patients with extensive-stage SCLC.